U.S. flag

An official website of the United States government

Format
Sort by

Send to:

Choose Destination

Search results

Items: 5

1.

An EGFR-mutation signature reveals features of the EGFR-dependent phenotype and identifies MACC1 as an EGFR-associated regulator of MET.

(Submitter supplied) EGFR-mutated non-small cell lung cancers bear hallmarks including sensitivity to EGFR inhibitors, and low proliferation, and increased MET. However, the biology of EGFR dependence is still poorly understood. Using a training cohort of chemo-naive lung adenocarcinomas, we have developed a 72-gene signature that predicts (i) EGFR mutation status in four independent datasets; (ii) sensitivity to erlotinib in vitro; and (iii) improved survival, even in the wild-type EGFR subgroup. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL6244
124 Samples
Download data: CEL
Series
Accession:
GSE31852
ID:
200031852
2.

An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to erlotinib and PI3K pathway inhibitors and identifies Axl as a novel EMT marker in non-small cell lung cancer.

(Submitter supplied) Epithelial/mesenchymal transition (EMT) is associated with loss of cell adhesion molecules, such as E-cadherin, and increased invasion, migration, and proliferation in epithelial cancers. In non-small cell lung cancer (NSCLC), EMT is associated with greater resistance to EGFR inhibitors. However, its potential to predict response to other targeted drugs or chemotherapy has not been well characterized. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL6244
131 Samples
Download data: CEL
Series
Accession:
GSE33072
ID:
200033072
3.

Substitutions in the KRas oncogene determine protein behavior: Implications for signaling and clinical outcome.

(Submitter supplied) Mutant KRAS (mut-KRAS) is present in 30% of all human cancers and plays a critical role in cancer cell growth and resistance to therapy. There is evidence from colon cancer that mut-KRAS is a poor prognostic factor and negative predictor of patient response to molecularly targeted therapy. However, evidence for such a relationship in non small cell lung cancer (NSCLC) is conflicting. KRAS mutations are primarily found at codons 12 and 13, where different base changes lead to alternate amino acid substitutions that lock the protein in an active state. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL6244
22 Samples
Download data: CEL
Series
Accession:
GSE27389
ID:
200027389
4.

[HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version]

(Submitter supplied) Affymetrix submissions are typically submitted to GEO using the GEOarchive method described at http://www.ncbi.nlm.nih.gov/projects/geo/info/geo_affy.html June 03, 2009: annotation table updated with netaffx build 28 June 18, 2012: annotation table updated with netaffx build 32 July 01, 2016: annotation table updated with netaffx build 35 Protocol: See manufacturer's web site
Organism:
Homo sapiens
136 DataSets
1879 Series
27 Related Platforms
38399 Samples
Download data
Platform
Accession:
GPL6244
ID:
100006244
5.

LM233

Organism:
Homo sapiens
Source name:
BATTLE_trial_core biopsy_chemorefractory non-small cell lung cancer
Platform:
GPL6244
Series:
GSE27389 GSE31852 GSE33072
Download data: CEL
Sample
Accession:
GSM677325
ID:
300677325
Format
Sort by

Send to:

Choose Destination

Supplemental Content

db=gds|term=GSM677325[Accession]|query=1|qty=2|blobid=MCID_67596024c087e367329b2c54|ismultiple=true|min_list=5|max_list=20|def_tree=20|def_list=|def_view=|url=/Taxonomy/backend/subset.cgi?|trace_url=/stat?
   Taxonomic Groups  [List]
Tree placeholder
    Top Organisms  [Tree]

Find related data

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center